Single-Port <i>vs</i> Multiport Robotic Surgery in Urologic Oncology: A Narrative Review

摘要

Introduction: Robotic surgery has improved the oncologic and functional outcomes of many urologic oncology procedures by optimizing visualization and instrument maneuverability. Since its FDA approval in 2018, the daVinci single-port (SP) platform has become increasingly utilized in urologic oncology, with its theoretical advantages over the standard multiport (MP) platform including improved cosmesis, reduced pain, and shorter hospitalization. Given this platform’s relative novelty, comparisons between SP and MP robotic surgeries in urologic oncology tend to be small, non-randomized studies performed at centers of excellence. We review the existing literature comparing oncologic and functional outcomes between SP and MP surgeries to treat prostate, kidney, and bladder cancer.